UNI-EN 74:Notification
Firma: SOPHARMA ADSpis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| UNI - EN REPORT No | 74 | / | 2015 | | ||||||
Date of issue: | 2015-08-04 | ||||||||||
Short name of the issuer | |||||||||||
SOPHARMA AD | |||||||||||
Subject | |||||||||||
Notification | |||||||||||
Official market - legal basis | |||||||||||
Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne | |||||||||||
Unofficial market - legal basis | |||||||||||
Contents of the report: | |||||||||||
Sopharma AD (the “Company") hereby notifies that on 4 August 2015 Sopharma AD received a notification of disclosure of shareholdings from Telso AD regarding the selling of 397 057 shares. After this transaction the share of Telso AD in the capital of Sopharma AD decreased below 5%. The date of registration of the transaction with the Central Depository AD is 31 July 2015. | |||||||||||
Annexes | |||||||||||
File | Description | ||||||||||
current report 74 d_uchastie_Telso_pod 5%_04082015 ENG.doc current report 74 d_uchastie_Telso_pod 5%_04082015 ENG.doc | Notification |
SOPHARMA AD | |||||||||||||
(fullname of the issuer) | |||||||||||||
SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
(short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
1220 | Sofia | ||||||||||||
(post code) | (city) | ||||||||||||
IlienskoShosse | 16 | ||||||||||||
(street) | (number) | ||||||||||||
+359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
(phone number) | (fax) | ||||||||||||
(e-mail) | (web site) | ||||||||||||
nd | |||||||||||||
(NIP) | (REGON) |
SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
Date | Name | Position / Function | Signature | ||
2015-08-04 | Ognian Donev | Executive director |
Cena akcji Sopharma
Cena akcji Sopharma w momencie publikacji komunikatu to 6.01 PLN. Sprawdź ile kosztuje akcja Sopharma aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Sopharma.